GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Pharmarise Holdings Corp (TSE:2796) » Definitions » ROE %

Pharmarise Holdings (TSE:2796) ROE % : -27.73% (As of May. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Pharmarise Holdings ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Pharmarise Holdings's annualized net income for the quarter that ended in May. 2024 was 円-2,112 Mil. Pharmarise Holdings's average Total Stockholders Equity over the quarter that ended in May. 2024 was 円7,616 Mil. Therefore, Pharmarise Holdings's annualized ROE % for the quarter that ended in May. 2024 was -27.73%.

The historical rank and industry rank for Pharmarise Holdings's ROE % or its related term are showing as below:

TSE:2796' s ROE % Range Over the Past 10 Years
Min: -4.93   Med: 4.53   Max: 10.15
Current: -4.71

During the past 13 years, Pharmarise Holdings's highest ROE % was 10.15%. The lowest was -4.93%. And the median was 4.53%.

TSE:2796's ROE % is ranked worse than
70.08% of 625 companies
in the Healthcare Providers & Services industry
Industry Median: 4.77 vs TSE:2796: -4.71

Pharmarise Holdings ROE % Historical Data

The historical data trend for Pharmarise Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmarise Holdings ROE % Chart

Pharmarise Holdings Annual Data
Trend May15 May16 May17 May18 May19 May20 May21 May22 May23 May24
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.15 7.03 6.97 4.94 -4.93

Pharmarise Holdings Quarterly Data
Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.35 7.15 7.90 -4.75 -27.73

Competitive Comparison of Pharmarise Holdings's ROE %

For the Pharmaceutical Retailers subindustry, Pharmarise Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmarise Holdings's ROE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Pharmarise Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where Pharmarise Holdings's ROE % falls into.



Pharmarise Holdings ROE % Calculation

Pharmarise Holdings's annualized ROE % for the fiscal year that ended in May. 2024 is calculated as

ROE %=Net Income (A: May. 2024 )/( (Total Stockholders Equity (A: May. 2023 )+Total Stockholders Equity (A: May. 2024 ))/ count )
=-351/( (6881+7360)/ 2 )
=-351/7120.5
=-4.93 %

Pharmarise Holdings's annualized ROE % for the quarter that ended in May. 2024 is calculated as

ROE %=Net Income (Q: May. 2024 )/( (Total Stockholders Equity (Q: Feb. 2024 )+Total Stockholders Equity (Q: May. 2024 ))/ count )
=-2112/( (7872+7360)/ 2 )
=-2112/7616
=-27.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (May. 2024) net income data. ROE % is displayed in the 30-year financial page.


Pharmarise Holdings  (TSE:2796) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: May. 2024 )
=Net Income/Total Stockholders Equity
=-2112/7616
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-2112 / 55168)*(55168 / 27955.5)*(27955.5 / 7616)
=Net Margin %*Asset Turnover*Equity Multiplier
=-3.83 %*1.9734*3.6706
=ROA %*Equity Multiplier
=-7.56 %*3.6706
=-27.73 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: May. 2024 )
=Net Income/Total Stockholders Equity
=-2112/7616
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-2112 / -2472) * (-2472 / 212) * (212 / 55168) * (55168 / 27955.5) * (27955.5 / 7616)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.8544 * -11.6604 * 0.38 % * 1.9734 * 3.6706
=-27.73 %

Note: The net income data used here is four times the quarterly (May. 2024) net income data. The Revenue data used here is four times the quarterly (May. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Pharmarise Holdings ROE % Related Terms

Thank you for viewing the detailed overview of Pharmarise Holdings's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmarise Holdings Business Description

Traded in Other Exchanges
N/A
Address
8 Floor, Sumitomo Nakano Sakue Building, 1-38-1 Chuo, Nakano-ku, Tokyo, JPN, 164-0011
Pharmarise Holdings Corp is engaged in the operation of dispensing pharmacies, which prescribe medicines to general patients based on prescriptions issued by medical institutions. It is also engaged in the storage and management of medical examination records of patients on behalf of the medical institution.

Pharmarise Holdings Headlines

No Headlines